Abstract
Histone deacetylases (HDACs) regulate gene expression by modulating chromatin architecture via histone hypoacetylation. They play a key role in regulating cellular processes including cell cycle arrest and apoptosis. Hyperactivity of HDACs plays a key role in tumour onset and progression making these enzymes as striking targets for anticancer drugs and therapy. Certain cancers are associated with upregulation of specific class II HDAC isoform rather than multiple ones. Therapeutic intervention using small-molecules namely histone deacetylase inhibitors (HDACi), often targets many isoforms unselectively (pan-HDACi) due to structural identity culminating in debilitating off-target effects and reduced in vivo potency. This emphasizes the escalating need for developing isoform-selective inhibitors against the defined class of HDACs. Despite the safe and elevated therapeutic benefit, the design of such inhibitors has been challenging. The present article provides intricate details about the role of class II HDAC isoforms in fuelling distinct cancers and the current challenges with the use of pan-HDAC inhibitors in anticancer therapy. The article also highlights the diverse synthetic and in silico approaches taken by scientific community towards the designing of isoform-selective inhibitors against class II HDAC isoforms. The strategies discussed in this review will provide further impetus to the ongoing research regarding the designing of isoform-selective inhibitors for safe and effective anticancer therapy which is today’s need.
Keywords: Histone deacetylases, Histone deacetylase inhibitors, Pan-inhibitors, Isoform-selective inhibitors, Cancer.
Current Topics in Medicinal Chemistry
Title:Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Volume: 16 Issue: 22
Author(s): Shabir Ahmad Ganai
Affiliation:
Keywords: Histone deacetylases, Histone deacetylase inhibitors, Pan-inhibitors, Isoform-selective inhibitors, Cancer.
Abstract: Histone deacetylases (HDACs) regulate gene expression by modulating chromatin architecture via histone hypoacetylation. They play a key role in regulating cellular processes including cell cycle arrest and apoptosis. Hyperactivity of HDACs plays a key role in tumour onset and progression making these enzymes as striking targets for anticancer drugs and therapy. Certain cancers are associated with upregulation of specific class II HDAC isoform rather than multiple ones. Therapeutic intervention using small-molecules namely histone deacetylase inhibitors (HDACi), often targets many isoforms unselectively (pan-HDACi) due to structural identity culminating in debilitating off-target effects and reduced in vivo potency. This emphasizes the escalating need for developing isoform-selective inhibitors against the defined class of HDACs. Despite the safe and elevated therapeutic benefit, the design of such inhibitors has been challenging. The present article provides intricate details about the role of class II HDAC isoforms in fuelling distinct cancers and the current challenges with the use of pan-HDAC inhibitors in anticancer therapy. The article also highlights the diverse synthetic and in silico approaches taken by scientific community towards the designing of isoform-selective inhibitors against class II HDAC isoforms. The strategies discussed in this review will provide further impetus to the ongoing research regarding the designing of isoform-selective inhibitors for safe and effective anticancer therapy which is today’s need.
Export Options
About this article
Cite this article as:
Ganai Ahmad Shabir, Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy, Current Topics in Medicinal Chemistry 2016; 16 (22) . https://dx.doi.org/10.2174/1568026616666160212122609
DOI https://dx.doi.org/10.2174/1568026616666160212122609 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Carcinogenicity and Chronic Rodent Toxicity of the Selective Progesterone Receptor Modulator Ulipristal Acetate
Current Drug Safety The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Computational Docking Studies of Novel Heterocyclic Carboxamides as Potential PI3Kα Inhibitors
Letters in Drug Design & Discovery Diabetic Gastroenteropathy: Soothe the Symptoms or Unravel a Cure?
Current Diabetes Reviews Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Editorial [Hot Topic: The RB-Pathway in Cancer (Executive Editor: Erik Knudsen)]
Current Molecular Medicine Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences
Central Nervous System Agents in Medicinal Chemistry The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Releasing of Herpes Simplex Virus Carrying NGF in Subarachnoid Space Promotes the Functional Repair in Spinal Cord Injured Rats
Current Gene Therapy Particle Sorting in Microfluidic Systems
Micro and Nanosystems Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mini-Reviews in Medicinal Chemistry Patent Annotations
Recent Patents on DNA & Gene Sequences Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Combination of Valproic Acid and ATRA Restores RARβ2 Expression and Induces Differentiation in Cervical Cancer through the PI3K/Akt Pathway
Current Molecular Medicine Regulation of Apoptosis and Cell Survival by Resveratrol
Mini-Reviews in Organic Chemistry System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry